

List of Publications by Citations

Source: <https://exaly.com/author-pdf/2136031/puja-mehta-publications-by-citations.pdf>
Version: 2024-04-09

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.
The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

40 papers	6,280 citations	14 h-index	47 g-index
47 ext. papers	8,109 ext. citations	9.7 avg, IF	7.06 L-index

#	Paper	IF	Citations
40	COVID-19: consider cytokine storm syndromes and immunosuppression. <i>Lancet, The</i> , 2020 , 395, 1033-1034	14.2	5500
39	COVID-19-associated hyperinflammation and escalation of patient care: a retrospective longitudinal cohort study. <i>Lancet Rheumatology, The</i> , 2020 , 2, e594-e602	14.2	141
38	Silencing the cytokine storm: the use of intravenous anakinra in haemophagocytic lymphohistiocytosis or macrophage activation syndrome. <i>Lancet Rheumatology, The</i> , 2020 , 2, e358-e367	14.2	120
37	In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib. <i>Blood</i> , 2008 , 111, 2378-81	2.2	78
36	Therapeutic blockade of granulocyte macrophage colony-stimulating factor in COVID-19-associated hyperinflammation: challenges and opportunities. <i>Lancet Respiratory Medicine, the</i> , 2020 , 8, 822-830	35.1	72
35	SLE with C1q deficiency treated with fresh frozen plasma: a 10-year experience. <i>Rheumatology</i> , 2010 , 49, 823-4	3.9	44
34	B-cell depletion with rituximab in the COVID-19 pandemic: where do we stand?. <i>Lancet Rheumatology, The</i> , 2020 , 2, e589-e590	14.2	41
33	JAK inhibitors in COVID-19: the need for vigilance regarding increased inherent thrombotic risk. <i>European Respiratory Journal</i> , 2020 , 56,	13.6	35
32	The intersection of COVID-19 and autoimmunity. <i>Journal of Clinical Investigation</i> , 2021 ,	15.9	22
31	Avascular necrosis in HIV. <i>Rheumatology International</i> , 2013 , 33, 235-8	3.6	21
30	Is severe COVID-19 a cytokine storm syndrome: a hyperinflammatory debate. <i>Current Opinion in Rheumatology</i> , 2021 , 33, 419-430	5.3	18
29	Local and systemic responses to SARS-CoV-2 infection in children and adults.. <i>Nature</i> , 2021 ,	50.4	17
28	Novel compound heterozygous mutations in ENPP1 cause hypophosphataemic rickets with anterior spinal ligament ossification. <i>Rheumatology</i> , 2012 , 51, 1919-21	3.9	15
27	Outcomes of COVID-19 in patients with primary systemic vasculitis or polymyalgia rheumatica from the COVID-19 Global Rheumatology Alliance physician registry: a retrospective cohort study. <i>Lancet Rheumatology, The</i> , 2021 , 3, e855-e864	14.2	11
26	Is fibromyalgia associated with a unique cytokine profile? A systematic review and meta-analysis. <i>Rheumatology</i> , 2021 , 60, 2602-2614	3.9	11
25	What Is the Clinical Relevance of TNF Inhibitor Immunogenicity in the Management of Patients With Rheumatoid Arthritis?. <i>Frontiers in Immunology</i> , 2020 , 11, 589	8.4	10
24	Giant Cell Arteritis and COVID-19: Similarities and Discriminators. A Systematic Literature Review. <i>Journal of Rheumatology</i> , 2021 , 48, 1053-1059	4.1	10

23	Thromboses and COVID-19: reducing inflammation in addition to thromboprophylaxis. <i>Lancet Rheumatology, The</i> , 2021 , 3, e171-e172	14.2	10
22	Clinical pathways for patients with giant cell arteritis during the COVID-19 pandemic: an international perspective. <i>Lancet Rheumatology, The</i> , 2021 , 3, e71-e82	14.2	9
21	Post-COVID-19 assessment in a specialist clinical service: a 12-month, single-centre, prospective study in 1325 individuals. <i>BMJ Open Respiratory Research</i> , 2021 , 8,	5.6	7
20	Chilblain-like acral lesions in long COVID-19: management and implications for understanding microangiopathy. <i>Lancet Infectious Diseases, The</i> , 2021 , 21, 912	25.5	7
19	Difficult case: rituximab in anti-SRP antibody myositis in pregnancy. <i>Practical Neurology</i> , 2019 , 19, 444-446	4.4	6
18	The Rapunzel syndrome: is it an Asian problem? (case report and review of literature). <i>European Journal of Gastroenterology and Hepatology</i> , 2009 , 21, 937-40	2.2	6
17	EULAR recommendations for the management and vaccination of people with rheumatic and musculoskeletal diseases in the context of SARS-CoV-2: the November 2021 update.. <i>Annals of the Rheumatic Diseases</i> , 2022 ,	2.4	6
16	Influenza vaccination and interruption of methotrexate in adult patients in the COVID-19 era: an ongoing dilemma. <i>Lancet Rheumatology, The</i> , 2021 , 3, e9-e10	14.2	5
15	Intravenous anakinra for cytokine storm syndromes - AuthorsTreply. <i>Lancet Rheumatology, The</i> , 2020 , 2, e522-e523	14.2	4
14	Steroid-resistant remitting seronegative symmetrical synovitis with pitting oedema associated with gout treated with etanercept. <i>Rheumatology</i> , 2014 , 53, 1908-10	3.9	3
13	Lateral medullary syndrome with anti-neuronal antibodies (anti-Ta/Ma2) in primary Sjogren's syndrome. <i>Rheumatology</i> , 2009 , 48, 1174-6	3.9	3
12	The local and systemic response to SARS-CoV-2 infection in children and adults		3
11	Post-COVID assessment in a specialist clinical service: a 12-month, single-centre analysis of symptoms and healthcare needs in 1325 individuals		3
10	Granulocyte-macrophage colony stimulating factor in COVID-19: friend or foe?. <i>Lancet Rheumatology, The</i> , 2021 , 3, e394-e395	14.2	3
9	A late presentation of Loeys-Dietz syndrome: joint hypermobility is not always benign. <i>Rheumatology</i> , 2014 , 53, 574-6	3.9	2
8	Aetiopathology of rheumatoid arthritis. <i>Medicine</i> , 2010 , 38, 163-166	0.6	2
7	Pain in Rheumatoid Arthritis: Could JAK Inhibition be the Answer?. <i>Mediterranean Journal of Rheumatology</i> , 2020 , 31, 112-119	1.4	2
6	Painful myositis in the anti-synthetase syndrome with anti-PL12 antibodies. <i>Rheumatology International</i> , 2012 , 32, 825-7	3.6	1

5	Variability in counselling for adrenal insufficiency in COVID-19 and beyond: a survey of rheumatology practice. <i>Lancet Rheumatology, The</i> , 2021 , 3, e92-e94	14.2	1
4	Targeting hyperinflammation in infection: can we harness the COVID-19 therapeutics momentum to end the dengue drugs drought?. <i>Lancet Microbe, The</i> , 2021 , 2, e277-e278	22.2	0
3	Dr. Conway et al reply.. <i>Journal of Rheumatology</i> , 2022 , 49, 120-121	4.1	
2	Central sensitisation: causes, therapies, and terminology. <i>Lancet Rheumatology, The</i> , 2021 , 3, e546-e547	14.2	
1	Self-perceived disease activity was the strongest predictor of COVID-19 pandemic-related concerns in young people with autoimmune rheumatic diseases, irrespective of their gender, with females reporting higher concerns.. <i>Rheumatology Advances in Practice</i> , 2022 , 6, rkac031	1.1	